<![CDATA[Renal cell carcinoma (RCC) in Indonesia is frequently diagnosed at an advanced stage. Although immune checkpoint inhibitor-based combinations are recommended as first-line therapy, access remains limited in many public healthcare settings, and pazopanib continues to be widely used in routine clinical practice. This single-center observational study evaluated real-world outcomes of pazopanib in adult patients with stage IV RCC treated at a tertiary referral center in Indonesia between January 2020 and December 2025; patients treated for less than one month were excluded. Overall survival (OS) was estimated using the Kaplan–Meier method, while disease progression and treatment exposure were analyzed descriptively. Sixteen patients were included. Median age was 54 years (range, 24–69), and clear-cell RCC was the predominant histological subtype (93.8%). Disease progression occurred in 8 patients (50.0%), most commonly in the lungs. At the end of follow-up, 5 patients (31.3%) were alive, 5 (31.3%) had died, and 6 (37.5%) were lost to follow-up. Mean OS was 29.5 months (95% CI, 18.2–40.7 months), while median OS was not reached. Pazopanib remains a feasible treatment option for selected patients with stage IV RCC in resource-constrained settings where access to immunotherapy is limited.]]>
Copyrights © 2026
